Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation.
Eva NeumannPeter KlaiberKathleen FreitagMatthias SchwabElke SchaeffelerJörg HennenlotterFalko FendStephan KruckMarcus ScharpfArnulf StenzlJens BedkeSteffen RauschPublished in: Journal of cancer research and clinical oncology (2019)
Concomitant intake of statins and sartans identifies as an independent predictor of OS in RCC, and reduced Ki67 expression was significantly associated with statin use. Further evaluation of drug repurposing approaches with these substances in RCC appear warranted.
Keyphrases
- renal cell carcinoma
- cell cycle
- cardiovascular disease
- cell proliferation
- poor prognosis
- adverse drug
- signaling pathway
- genome wide
- coronary artery disease
- healthcare
- drinking water
- rectal cancer
- neoadjuvant chemotherapy
- prostate cancer
- emergency department
- weight gain
- gene expression
- type diabetes
- dna methylation
- long non coding rna
- radiation therapy
- newly diagnosed
- squamous cell carcinoma